Adoptive immunotherapies after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies
Hematopoietic stem cell transplantation (HSCT) is the only curative therapy for patients with chemotherapy-resistant hematological malignancies which are usually fatal in absence of treatment. HSCT is associated with significant early and late morbidity and mortality. Graft-versus-host disease, infections and relapse are the most important causes of mortality after HSCT. Until now, these complications have been managed mainly with pharmacological drugs but in some situations this approach clearly shows its limit.
Source: Transfusion Medicine Reviews - Category: Hematology Authors: Yu Xiong, Danièle Bensoussan, Véronique Decot Source Type: research
More News: Cancer & Oncology | Chemotherapy | Hematology | Immunotherapy | Stem Cell Therapy | Stem Cells | Transplants